Published in Infect Immun on January 01, 1971
Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev (1983) 5.73
Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br Med J (1972) 5.14
The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity. J Clin Invest (1976) 1.94
Effects of phagocytosis by rabbit granulocytes on macromolecular synthesis and degradation in different species of bacteria. J Bacteriol (1973) 1.87
Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme. Infect Immun (1980) 1.40
Killing of an encapsulated strain of Escherichia coli by human serum. Infect Immun (1983) 1.35
Effects of human and rabbit serum on viability, permeability, and envelope lipids of Serratia marcescens. Infect Immun (1975) 1.23
Constitutive uptake and degradation of fatty acids by Yersinia pestis. J Bacteriol (1983) 0.86
Structural insights into RipC, a putative citrate lyase β subunit from a Yersinia pestis virulence operon. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.81
Resistance of Escherichia coli to osmotically introduced complement component C9. Infect Immun (1991) 0.80
Determination of serum bactericidal activity with the aid of luminous bacteria. J Clin Microbiol (1983) 0.75
Influence of antibodies to mannophosphoinositides on phospholipid synthesis in Mycobacterium smegmatis ATCC 607. Infect Immun (1982) 0.75
Effect of serum on phospholipids of L-forms of Streptococcus faecalis. Infect Immun (1976) 0.75
Amino acid metabolism in mammalian cell cultures. Science (1959) 55.21
KINETICS OF THE BACTERICIDAL ACTION OF NORMAL SERUM ON GRAM-NEGATIVE BACTERIA. J Immunol (1965) 2.80
Patterns of cellular control during unbalanced growth. Cold Spring Harb Symp Quant Biol (1961) 2.70
Thymidine and thymine incorporation into deoxyribonucleic acid: inhibition and repression by uridine of thymidine phosphorylase of Escherichia coli. J Bacteriol (1967) 2.41
Locus of the lethal event in the serum bactericidal reaction. J Bacteriol (1968) 2.35
Normal serum cytotoxicity for P32-labeled smooth Enterobacteriaceae. I. Loss of label, death, and ultrastructural damage. J Bacteriol (1966) 2.30
Locus of the action of serum and the role of lysozyme in the serum bactericidal reaction. J Bacteriol (1968) 1.99
Lesions in Escherichia coli membranes after action of antibody and complement. J Bacteriol (1966) 1.94
A rapid radioassay technique for cellular suspensions. Anal Biochem (1966) 1.91
IMMUNE BACTERICIDAL ACTIVITY OF COMPLEMENT. SEPARATION AND DESCRIPTION OF INTERMEDIATE STEPS. J Immunol (1964) 1.82
Molecular and structural damage to Escherichia coli produced by antibody, complement, and lysozyme systems. J Bacteriol (1968) 1.64
Lipid synthesis in relation to the cell cycle of Bacillus megaterium KM and Escherichia coli. Biochem J (1969) 1.62
Effect of hypertonic sucrose upon the immune bactericidal reaction. Infect Immun (1970) 1.51
Normal serum cytotoxicity for P32-labeled smooth Enterobacteriaceae. II. Fate of macromolecular and lipid phosphorus of damaged cells. J Bacteriol (1966) 1.44
Sensitization of complement resistant bacterial strains. Nature (1969) 1.40
Reversal of the bactericidal reaction of serum by magnesium ion. J Bacteriol (1966) 1.39
Biology and pathogenicity of microbial spheroplasts and l-forms. N Engl J Med (1969) 1.33
Respiration and protein synthesis in Escherichia coli membrane-envelope fragments. I. Oxidative activities with soluble substrates. J Cell Biol (1969) 1.13
Effect of renal physico-chemical milieu on serum bactericidal activity. Am J Med Sci (1967) 1.06
Effects of Ehrlich ascites antisera on the biochemical activities of Ehrlich ascites carcinoma cells in vitro. Cancer Res (1959) 0.96
The effects of serum components on the agglutination of Gram-negative bacteria. Can J Microbiol (1970) 0.88
In vitro effects of heterologous antibodies on the metabolism and fine structure of Yoshida ascites hepatoma cells. Sperimentale (1970) 0.79
Resistance of inbred mice to Salmonella typhimurium. J Infect Dis (1972) 4.32
Microbiologic aspects of chronic ambulatory peritoneal dialysis. Kidney Int (1983) 2.66
Continuous ambulatory peritoneal dialysis - 1981. Nephron (1982) 1.82
Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int (1998) 1.78
Effect of nonspecific stimulation on the defense mechanisms of inbred mice. J Immunol (1975) 1.72
Microbiological diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol (1985) 1.51
Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int (2001) 1.47
Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int (1999) 1.44
Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol (1989) 1.40
Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun (1981) 1.29
In vitro cytotoxicity and antibiotic activity of polymyxin B nonapeptide. Antimicrob Agents Chemother (1986) 1.12
Specific antibody-mediated effect on the immune response. Suppression and augmentation of the primary immune response in mice by different classes of antibodies. Immunology (1972) 1.11
Endotoxin sensitivity of inbred mouse strains. Can J Microbiol (1973) 1.05
Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant (2001) 0.99
Effects of antibodies on L5178Y mouse leukemia cells cultured in vitro. Cancer Res (1970) 0.91
Staph aureus peritonitis in patients on continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs (1984) 0.90
Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit. Clin Nephrol (1988) 0.89
The effects of serum components on the agglutination of Gram-negative bacteria. Can J Microbiol (1970) 0.88
Response to hepatitis B vaccine in Canadian dental students. Lancet (1982) 0.88
Outcome of Pseudomonas aeruginosa exit-site and tunnel infections: a single center's experience. Adv Perit Dial (1999) 0.87
Renal cell carcinoma in peritoneal dialysis patients. Int Urol Nephrol (2003) 0.87
Comparison of "invasive" and "non-invasive" strains of Staphylococcus epidermidis by phage typing. Zentralbl Bakteriol Orig A (1978) 0.86
Isoelectric separation of mouse immunoglobulins. J Immunol (1970) 0.84
Management of abdominal aortic and iliac artery aneurysms by stent-graft implantation in a patient on CAPD. Clin Nephrol (2009) 0.82
Peritonitis in continuous ambulatory peritoneal dialysis. Making therapeutic decisions easier. Arch Intern Med (1987) 0.81
Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int (1999) 0.81
Growth inhibitory effects of adenosine 3',5'-monophosphate on mouse leukemia L-5178-Y-R cells in culture. Experientia (1971) 0.80
Chronic peritoneal dialysis in octogenarians. Nephrol Dial Transplant (2001) 0.80
The effect of small solute clearances on survival of anuric peritoneal dialysis patients. Perit Dial Int (2000) 0.77
Biocompatibility of silver-coated peritoneal dialysis catheter in a porcine model. Perit Dial Int (1997) 0.77
Recurrence of hyperparathyroidism after total parathyroidectomy and autotransplantation in peritoneal dialysis patients. Perit Dial Int (2000) 0.75
Effects of endotoxin on carbohydrate metabolism in inbred mice. Can J Comp Med (1976) 0.75
Continuous ambulatory peritoneal dialysis: no longer experimental. Can Med Assoc J (1984) 0.75
Treatment of peritonitis: how are we doing? Perit Dial Int (1995) 0.75
Treatment of peritonitis: update or new course. Perit Dial Int (2001) 0.75
Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe? Perit Dial Int (1999) 0.75
Treatment of fungal peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Am J Med (1990) 0.75
A large step in the treatment of peritonitis in peritoneal dialysis patients. Perit Dial Int (1997) 0.75
The alphabet-soup of hepatitis. Perit Dial Int (1992) 0.75
Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient. Am J Kidney Dis (1990) 0.75
Studies on the production of complement. Immunology (1968) 0.75
Importance of family contacts of HAA-positive persons. N Engl J Med (1972) 0.75
Inhibition of RNA, DNA and protein synthesis by antisera in mouse leukemic cells L5178YR. Exp Cell Res (1972) 0.75
Is catheter function influenced by the side of the body in which the peritoneal dialysis catheter is placed? Perit Dial Int (2001) 0.75
VRE and empirical vancomycin for CAPD peritonitis: use at your own/patient's risk. Perit Dial Int (1998) 0.75
Local application of mupirocin at the peritoneal catheter exit site prevents early postoperative infections and should become standard practice. Perit Dial Int (2001) 0.75
Etiology and treatment of peritonitis. Trans Am Soc Artif Intern Organs (1984) 0.75
Inhibitory effects of anticellular antibodies on colony formation of mouse leukemia L5178YR cells in soft agar. Can J Microbiol (1972) 0.75
Handle with care: hepatitis B antigen carriers in peritoneal dialysis unit. Nephron (1981) 0.75
Long-term, intraperitoneal vancomycin in the prevention of recurrent peritonitis during CAPD: preliminary results. Perit Dial Int (1991) 0.75
Environmental protection and peritoneal dialysis garbage. Perit Dial Int (1991) 0.75
Heated sera and laboratory tests. Ann Intern Med (1985) 0.75
Update on continuous ambulatory peritoneal dialysis. Ric Clin Lab (1984) 0.75
Effects of immunosuppressive drugs on secondary antibody response in vitro. Can J Microbiol (1968) 0.75
Quantitation of macrophage activation. Acta Microbiol Hung (1983) 0.75
Hepatitis B and the dental profession: response to hepatitis B vaccine in Canadian dental personnel. A study by the Canadian Red Cross Collaborative Group. J Infect (1983) 0.75
Vaccination for peritoneal dialysis patients. Perit Dial Int (1999) 0.75
Prophylactic cephalexin ineffective in chronic ambulatory peritoneal dialysis. Lancet (1980) 0.75